TY  - JOUR 
AU  - Penarrubia, M. J.
AU  - Odriozola, J.
AU  - González, C.
AU  - Massagué, I.
AU  - Miguel, A.
AU  - González San Miguel, J. D.
AU  - Pérez Encinas, Manuel Mateo
AU  - Lavilla Rubira, Esperanza
AU  - Giraldo, M. P.
AU  - Casado, L. F.
AU  - Ferrer, S.
AU  - Steegmann, J. L.
PY  - 2003
UR  - http://hdl.handle.net/20.500.11940/22522
AB  - [EN] Interferon-alpha (IFN-alpha) is a therapy of unquestionable efficacy in chronic myeloid leukemia (CML) patients. The best dose of IFN-alpha in the treatment of CML still remains controversial. Our primary objective was to compare cytogenetic...
LA  - eng
KW  - Dose-Response Relationship, Drug
KW  - Spain
KW  - Follow-Up Studies
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Interferon-alpha
KW  - Cytogenetic Analysis
KW  - Survival Analysis
KW  - Clinical Trial
KW  - Antineoplastic Agents
TI  - A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses
DO  - 10.1007/s00277-003-0724-z
T2  - Annals of Hematology
M2  - 750
KW  - CHUS
KW  - CHULA
VL  - 82
ER  -